TW202106715A - 藉由多肽鏈交換活化之治療性多特異性多肽 - Google Patents

藉由多肽鏈交換活化之治療性多特異性多肽 Download PDF

Info

Publication number: TW202106715A
Authority: TW; Taiwan
Prior art keywords: domain; polypeptide; heterodimer; precursor; mutation
Prior art date: 2019-04-25

Application number

TW109113958A

Other languages

English (en)

Chinese (zh)

Inventor

奧里奇彼克曼儂

蓋喬治絲

俊沙賓因霍夫

史帝芬迪克歐普夫

柯恩包爾登

Original Assignee

瑞士商赫孚孟拉羅股份公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-04-25

Filing date

2020-04-24

Publication date

2021-02-16

2020-04-24 Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司

2021-02-16 Publication of TW202106715A publication Critical patent/TW202106715A/zh

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 1220
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 1152
229920001184 polypeptide Polymers 0.000 title claims abstract description 1148
230000001225 therapeutic effect Effects 0.000 title description 6
206010028980 Neoplasm Diseases 0.000 claims abstract description 12
201000011510 cancer Diseases 0.000 claims abstract description 11
239000000833 heterodimer Substances 0.000 claims description 514
239000002243 precursor Substances 0.000 claims description 509
230000035772 mutation Effects 0.000 claims description 411
239000000427 antigen Substances 0.000 claims description 329
102000036639 antigens Human genes 0.000 claims description 329
108091007433 antigens Proteins 0.000 claims description 329
230000027455 binding Effects 0.000 claims description 246
235000001014 amino acid Nutrition 0.000 claims description 175
150000001413 amino acids Chemical class 0.000 claims description 117
238000006467 substitution reaction Methods 0.000 claims description 81
125000003275 alpha amino acid group Chemical group 0.000 claims description 72
238000000034 method Methods 0.000 claims description 68
235000018417 cysteine Nutrition 0.000 claims description 44
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 44
230000002209 hydrophobic effect Effects 0.000 claims description 41
210000004899 c-terminal region Anatomy 0.000 claims description 28
238000004519 manufacturing process Methods 0.000 claims description 25
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 22
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
239000003638 chemical reducing agent Substances 0.000 claims description 12
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 8
239000001608 potassium adipate Substances 0.000 claims description 8
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 abstract description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 527
229940024606 amino acid Drugs 0.000 description 111
210000004027 cell Anatomy 0.000 description 79
230000000368 destabilizing effect Effects 0.000 description 70
239000000047 product Substances 0.000 description 63
125000005647 linker group Chemical group 0.000 description 52
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 40
150000007523 nucleic acids Chemical class 0.000 description 32
102000039446 nucleic acids Human genes 0.000 description 31
108020004707 nucleic acids Proteins 0.000 description 31
108090000623 proteins and genes Proteins 0.000 description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 18
230000007935 neutral effect Effects 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
239000004570 mortar (masonry) Substances 0.000 description 16
239000013598 vector Substances 0.000 description 16
230000014509 gene expression Effects 0.000 description 14
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 13
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 13
238000005516 engineering process Methods 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
239000000203 mixture Substances 0.000 description 12
125000003729 nucleotide group Chemical group 0.000 description 11
239000008194 pharmaceutical composition Substances 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
201000010099 disease Diseases 0.000 description 10
239000004471 Glycine Substances 0.000 description 9
108060003951 Immunoglobulin Proteins 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
238000004113 cell culture Methods 0.000 description 9
102000018358 immunoglobulin Human genes 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
-1 serine Chemical class 0.000 description 9
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
238000001042 affinity chromatography Methods 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
238000002372 labelling Methods 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000013604 expression vector Substances 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
238000001890 transfection Methods 0.000 description 7
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
230000006870 function Effects 0.000 description 6
230000036541 health Effects 0.000 description 6
238000005734 heterodimerization reaction Methods 0.000 description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
108010047041 Complementarity Determining Regions Proteins 0.000 description 5
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000003292 kidney cell Anatomy 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
239000000243 solution Substances 0.000 description 5
150000008163 sugars Chemical class 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
239000000178 monomer Substances 0.000 description 4
210000002706 plastid Anatomy 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
230000005180 public health Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
239000012124 Opti-MEM Substances 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000008859 change Effects 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000012258 culturing Methods 0.000 description 3
239000000539 dimer Substances 0.000 description 3
230000005750 disease progression Effects 0.000 description 3
239000012636 effector Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000007951 isotonicity adjuster Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
230000008569 process Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
238000001542 size-exclusion chromatography Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000003070 absorption delaying agent Substances 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
238000005251 capillar electrophoresis Methods 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000006167 equilibration buffer Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
244000005700 microbiome Species 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
210000000717 sertoli cell Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000577121 Homo sapiens Monocarboxylate transporter 3 Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
239000012515 MabSelect SuRe Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102100025275 Monocarboxylate transporter 3 Human genes 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical compound NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000012436 analytical size exclusion chromatography Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
BFTIPPVTTJTHLM-MNXVOIDGSA-N biocytinamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(N)=O)SC[C@@H]21 BFTIPPVTTJTHLM-MNXVOIDGSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical group COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
125000005022 dithioester group Chemical group 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
150000002243 furanoses Chemical class 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical group 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
229940065638 intron a Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
238000002823 phage display Methods 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
150000007970 thio esters Chemical group 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

TW109113958A 2019-04-25 2020-04-24 藉由多肽鏈交換活化之治療性多特異性多肽 TW202106715A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP19171069		2019-04-25
EP19171069.8		2019-04-25

Publications (1)

Publication Number	Publication Date
TW202106715A true TW202106715A (zh)	2021-02-16

Family

ID=66334198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW109113958A TW202106715A (zh)	2019-04-25	2020-04-24	藉由多肽鏈交換活化之治療性多特異性多肽

Country Status (12)

Country	Link
US (1)	US20220041722A1 (ja)
EP (1)	EP3959237A1 (ja)
JP (1)	JP2022530045A (ja)
KR (1)	KR20220004052A (ja)
CN (1)	CN113924314B (ja)
AU (1)	AU2020262309A1 (ja)
BR (1)	BR112021020859A2 (ja)
CA (1)	CA3132494A1 (ja)
IL (1)	IL287402A (ja)
MX (1)	MX2021012872A (ja)
TW (1)	TW202106715A (ja)
WO (1)	WO2020216879A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2022129313A1 (en) *	2020-12-18	2022-06-23	F. Hoffmann-La Roche Ag	Precursor proteins and kit for targeted therapy
WO2022170619A1 (en) *	2021-02-11	2022-08-18	Adagene Pte. Ltd.	Anti-cd3 antibodies and methods of use thereof
CA3227537A1 (en)	2021-07-27	2023-02-02	Morphosys Ag	Combinations of antigen binding molecules

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
ES2246069T3 (es)	1997-05-02	2006-02-01	Genentech, Inc.	Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
CA2385347C (en)	1999-10-04	2009-12-15	Medicago Inc.	Method for regulating transcription of foreign genes
TWI671403B (zh)	2005-03-31	2019-09-11	中外製藥股份有限公司	控制組裝之多肽的製造方法
AR060070A1 (es)	2006-03-24	2008-05-21	Merck Patent Gmbh	Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
PT2235064E (pt)	2008-01-07	2016-03-01	Amgen Inc	Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CA2759233C (en)	2009-04-27	2019-07-16	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
AU2010343056A1 (en)	2009-12-29	2012-08-02	Emergent Product Development Seattle, Llc	Ron binding constructs and methods of use thereof
CA2797981C (en)	2010-05-14	2019-04-23	Rinat Neuroscience Corporation	Heterodimeric proteins and methods for producing and purifying them
CN108341868B (zh)	2010-11-05	2022-06-07	酵活有限公司	在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2819530C (en) *	2010-11-30	2023-01-10	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
US9364549B2 (en) *	2011-11-30	2016-06-14	Andreas Voigt	Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
SI2794905T1 (sl)	2011-12-20	2020-08-31	Medimmune, Llc	Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
SG10201913376XA (en)	2012-04-20	2020-02-27	Merus Nv	Methods and means for the production of ig-like molecules
KR101522954B1 (ko) *	2012-11-27	2015-05-27	아주대학교산학협력단	항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
EP2985294A1 (en)	2014-08-14	2016-02-17	Deutsches Krebsforschungszentrum	Recombinant antibody molecule and its use for target cell restricted T cell activation
JP6721590B2 (ja) *	2014-12-03	2020-07-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性抗体
AU2015357053B2 (en) *	2014-12-05	2021-10-07	Merck Patent Gmbh	Domain-exchanged antibody
CN106883297B (zh) *	2015-12-16	2019-12-13	苏州康宁杰瑞生物科技有限公司	基于ch3结构域的异二聚体分子、其制备方法及用途
CN109153728A (zh) *	2016-03-21	2019-01-04	埃尔斯塔治疗公司	多特异性和多功能分子及其用途
CN111246885B (zh) *	2017-10-20	2024-06-11	豪夫迈·罗氏有限公司	从单特异性抗体生成多特异性抗体的方法
CN111372947A (zh) *	2017-10-30	2020-07-03	豪夫迈·罗氏有限公司	在体内从单特异性抗体产生多特异性抗体的方法
MX2020004571A (es) *	2017-11-01	2020-08-24	Hoffmann La Roche	Contorsbodies 2+1 biespecificos.

2020
- 2020-04-24 EP EP20722521.0A patent/EP3959237A1/en active Pending
- 2020-04-24 MX MX2021012872A patent/MX2021012872A/es unknown
- 2020-04-24 CN CN202080031058.6A patent/CN113924314B/zh active Active
- 2020-04-24 TW TW109113958A patent/TW202106715A/zh unknown
- 2020-04-24 AU AU2020262309A patent/AU2020262309A1/en active Pending
- 2020-04-24 BR BR112021020859A patent/BR112021020859A2/pt unknown
- 2020-04-24 CA CA3132494A patent/CA3132494A1/en active Pending
- 2020-04-24 JP JP2021562978A patent/JP2022530045A/ja active Pending
- 2020-04-24 KR KR1020217035283A patent/KR20220004052A/ko active Pending
- 2020-04-24 WO PCT/EP2020/061413 patent/WO2020216879A1/en unknown
2021
- 2021-10-19 IL IL287402A patent/IL287402A/en unknown
- 2021-10-21 US US17/507,029 patent/US20220041722A1/en active Pending

Also Published As

Publication number	Publication date
EP3959237A1 (en)	2022-03-02
US20220041722A1 (en)	2022-02-10
BR112021020859A2 (pt)	2022-01-04
CN113924314B (zh)	2024-10-18
AU2020262309A1 (en)	2021-10-14
CN113924314A (zh)	2022-01-11
CA3132494A1 (en)	2020-10-29
MX2021012872A (es)	2021-11-17
JP2022530045A (ja)	2022-06-27
IL287402A (en)	2021-12-01
WO2020216879A1 (en)	2020-10-29
KR20220004052A (ko)	2022-01-11

Publication	Publication Date	Title
US11999801B2 (en)	2024-06-04	Multispecific antibodies
CN113728002B (zh)	2024-11-12	通过多肽链交换产生抗体衍生的多肽
US10323099B2 (en)	2019-06-18	Multispecific domain exchanged common variable light chain antibodies
US20220041722A1 (en)	2022-02-10	Therapeutic multispecific polypeptides activated by polypeptide chain exchange
US20220033526A1 (en)	2022-02-03	Activatable therapeutic multispecific polypeptides with extended half-life
KR20150035535A (ko)	2015-04-06	Ig-유사 분자의 제조방법 및 제조수단
TR201809151T4 (tr)	2018-07-23	Bispesifik antikorların geliştirilmiş birleşmesi.
KR20200020703A (ko)	2020-02-26	이종이량체화 Ig 도메인
US20210054049A1 (en)	2021-02-25	Variant domains for multimerizing proteins and separation thereof
WO2024104988A1 (en)	2024-05-23	Recombinant binding proteins with activatable effector domain